Overview
Jialin Wang practices practicing medicine in Beijing, China.
Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.
She is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jialin Wang
Is Jialin Wang a top-rated expert for Glioblastoma?
MediFind is an objective health platform that identifies experts based on real-world data. Jialin Wang is classified as an Experienced expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jialin Wang participate in research or clinical trials?
Yes. Jialin Wang has published 8 articles and abstracts on conditions like Glioblastoma. You can view a list of Jialin Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- AstrocytomaMs. Wang isExperienced. Learn about Astrocytoma.
- Brain TumorMs. Wang isExperienced. Learn about Brain Tumor.
- GlioblastomaMs. Wang isExperienced. Learn about Glioblastoma.
- GliomaMs. Wang isExperienced. Learn about Glioma.
- Gliomatosis CerebriMs. Wang isExperienced. Learn about Gliomatosis Cerebri.